LungLife AI, INC Publication of AR and Accounts & Notice of AGM (7034H)
April 08 2022 - 2:01AM
UK Regulatory
TIDMLLAI
RNS Number : 7034H
LungLife AI, INC
08 April 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
Publication of Annual Report and Accounts & Notice of
AGM
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, announces that the Annual Report and
Accounts, Notice of Annual General Meeting ("AGM"), Form of
Direction and associated Form of Proxy are now available on the
Company's website and have been posted to those shareholders who
have opted out of electronic communications .
The documents are available here:
https://investors.lunglifeai.com/
The Company's AGM will be held at 2:00 P.M. (BST) on 11 May
2022, at Investec Bank plc, 30 Gresham Street, London, EC2V
7QP.
Following the easing of coronavirus (COVID-19) restrictions in
the UK, the Board has made arrangements to enable shareholders to
attend the Annual General Meeting in person. However, in light of
the uncertainty as to any further COVID-19 measures that may be put
in place by the UK Government and bearing in mind the inherent risk
of large gatherings, the Company encourages shareholders to
consider submitting their voting instructions in advance by
appointing the Chairman of the meeting as their proxy, rather than
attending and voting on the day. This will ensure that votes are
registered in accordance with shareholders' wishes regardless of
any restrictions or disruption around the Annual General Meeting
and will also help protect the health and safety of shareholders,
directors and other necessary attendees. Depending on the public
health situation, we may impose additional procedures or
limitations on attendees beyond any described in this Notice of the
Annual General Meeting. The Board will make arrangements for
shareholders to listen to proceedings remotely should they wish to
do so. We will announce details of how to listen to the meeting
remotely and any other significant changes to the meeting
arrangements via RNS and on our website at
https://investors.lunglifeai.com/
We strongly encourage you to vote by proxy, whether or not you
plan to attend the Company's Annual General Meeting in person.
Alternatively, you may register your votes on the resolutions of
the Annual General Meeting by completing and returning the proxy
form that accompanies the Notice in accordance with the
instructions printed on the proxy form. Or by using the link
www.signalshares.com and selecting LUNGLIFE AI, INC (You will need
to log into your Signal Shares account or register if you have not
previously done so. To register you will need your Investor Code,
this is detailed on your share certificate or available from our
Registrar, Link Group).
If your holding of Common Shares is by way of dematerialised
depository interests representing underlying Common Shares
("Depository Interests"), you can vote through the CREST system or
by returning a Form of Direction to the Depositary. Further
instructions are set out in the Notes to the Notice of Annual
General Meeting, available on the Company website.
The results of voting on the resolutions will be announced via a
regulatory information service and posted on the Company's website
as soon as practicable possible after the AGM.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Broker)
Daniel Adams / Virginia Bull / Cameron
MacRitchie
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 /
Marriage 0 7867 984 082
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOABKOBNPBKDFQK
(END) Dow Jones Newswires
April 08, 2022 02:01 ET (06:01 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Jun 2023 to Jun 2024